BIOE
Bio Essence Corporation0.0520
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.98MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
Bio Essence swung to profitability in Q2 FY2025 ended June 30, 2025, posting net income of $59,864 from continuing operations, up from a $215,678 loss a year earlier, while YTD net loss narrowed to $145,888 from $338,665 (y/y). Revenue rocketed 521% y/y to $259,123 in the quarter, all from outsourced manufacturing services after shedding unprofitable units, yielding a 65.1% gross margin—down slightly from 70.0% but on far higher volume. Operating income flipped to $61,223 from a $165,013 loss, driven by 44.7% lower G&A expenses like rent cuts, though YTD operating loss held at $143,869 amid startup selling costs. Cash from operations hit $141,728 YTD, funding shareholder loan repayments that left zero cash but $1.0M in such debt; SBA loans linger at $58,122 over 30 years at 3.75%. Customer concentration tops 70% of sales. Yet liquidity strains persist.
10-Q
Q1 FY2025 results
Bio Essence kicked off Q1 FY2025 with $22.2M in revenue from outsourced manufacturing services and shipping, up from zero a year ago after shedding unprofitable subsidiaries, though gross margins held at 92.8% on slim volumes. Operating losses widened to $205K y/y (derived), driven by G&A expenses jumping 48% to $225K on higher salaries, accounting, and consulting, while net losses hit $206K versus $123K prior, with the gap tied to absent one-time gains. Cash drained to zero amid $26K operating outflows, offset by $25K net shareholder loans, leaving a $3.2M current liability pile including $1.2M leases and $56K SBA debt at 3.75%. No non-GAAP metrics disclosed in the 10-Q. Customer concentration risks loom large, with five buyers claiming over 97% of sales.
10-K
FY2024 results
Bio Essence Corp. posted FY2024 revenue of $323,940 from continuing operations, up from nil in 2023, fueled by $37,415 in product sales and $282,752 in OEM services after selling manufacturing subsidiaries. Yet the company swung to a $1.6 million net loss from continuing operations, versus $405K last year, hammered by $1.1 million in other expenses including a $1.05 million ROU asset impairment from lease termination. Q4 momentum faltered amid subsidiary disposals in March and April, with cash at just $1,371 and a $2.5 million working capital deficit reliant on shareholder loans. No quarterly breakdowns disclosed. Losses mount fast.
10-Q
Q3 FY2024 results
Bio Essence kicked off revenue from continuing operations at $176K for the nine months ended September 30, 2024, up from zero a year ago, with gross margins holding steady at 62.5% on $110K profit before expenses ballooned to $573K, mainly from rent hikes. Q3 alone brought $135K in sales, yet a $1.05M right-of-use asset impairment slammed other expenses, driving a $1.2M quarterly net loss—far wider than 2023's $105K hit, while operating losses diverged from net by over 20% due to that impairment. Gains from unloading subsidiaries BEH and BEP in April and December 2023 for $400K and $300K cash, respectively, recognizing $378K goodwill-free goodwill, trimmed the nine-month net loss to $1.28M. Cash sits at $30K with $57K in government loans at 3.75% maturing over 30 years, but $1.6M shareholder debt looms large. Customer concentration risks persist, with three buyers topping 10% of sales.
IPO
Employees
Sector
Industry
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BIOA
BioAge Labs, Inc.
12.51+0.05
CANB
CAN B CORP.
0.02+0.00
CBDL
CBD Life Sciences Inc.
0.00+0.00
CVSI
CV Sciences, Inc.
0.03+0.00
HYEX
HEALTHY EXTRACTS INC.
1.99-0.22
INCR
Intercure Ltd.
1.45+0.05
NXEN
Nexien BioPharma, Inc.
0.00+0.00
RGC
Regencell Bioscience Holdings L
16.70-0.56
ZIVO
Zivo Bioscience, Inc.
9.00+0.00